CHICAGO — Temozolomide did not produce an OS equal to treatment with radiation therapy in elderly patients with anaplastic astrocytoma or glioblastoma, according to results from the phase-3 NOA-08 trial.
In fact, Wolfgang Wick, MD, medical director of the department of neuro-oncology at Heidelberg University Hospital, said it appears that temozolomide increased the risk for death in these patients.
Results of a Phase IIb study, presented at the American Association for Cancer Research 101st Annual Meeting 2010, showed a clear clinical benefit from trabedersen, a TGF-beta inhibitor, in patients with high-grade glioma; the Phase III study SAPPHIRE (NCT00761280) is currently enrolling.
"Current therapies for this patient population include surgery, radiation and chemotherapy with temozolomide," said...
* Merck to appeal decision on leading brain-cancer drug
* Teva generic awaiting U.S. approval
* Merck and Teva shares fractionally lower (Brings Merck response and detail of ruling higher; updates share movement)
By Ransdell Pierson
NEW YORK, Jan 26 (Reuters) - A federal court ruled on Tuesday that Merck & Co's (MRK.N) patent on Temodar, the world's top-selling brain cancer drug, is unenforceable, possibly...
ScienceDaily (Dec. 8, 2009) — University of Florida researchers have found a way to use just a fraction of the normal dosage of a highly toxic, debilitating chemotherapy drug to achieve even better results against colon cancer cells.
More research is needed before the therapy can be tested in patients, but the discovery in human colon cancer cell lines and mice with established human tumors suggests that the addition of a small molecule to the cancer drug Temozolomide disrupts repair...
Clinical Trials Launched for Treating Most Aggressive Brain Tumor With Personalized Cell Vaccines
ScienceDaily (Nov. 30, 2009) — The University of Navarra Hospital has launched a series of clinical trials in order to assess the efficacy of an immunotherapy treatment. This approach involves the application of personalised vaccines -- produced from healthy and tumour cells from the patient him or herself -- and designed to combat glioblastomas, one of the most aggressive and frequent...
